The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists

Behavioural Brain Research

Volumn 202, Issue 2, 2009, Pages 192-197

  Secchi, R L ^a   Sung, E ^a   Hedley, L R ^a   Button, D ^a   Schreiber, R ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Acoustic startle response; Amphetamine; Apomorphine; Pre pulse inhibition; Schizophrenia

Indexed keywords

APOMORPHINE; DEXAMPHETAMINE; DIZOCILPINE; NEUROTENSIN; NEUROTENSIN DERIVATIVE; NT 69 L; PEPTIDE; PSYCHEDELIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEGRADATION; EVALUATION; MALE; MEASUREMENT; MENTAL PATIENT; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORIMOTOR GATING DEFICIT; SENSORIMOTOR NEUROPATHY; STIMULUS RESPONSE;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; DEXTROAMPHETAMINE; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; NEUROTENSIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING; STARTLE REACTION; TIME FACTORS;

EID: 67349284271     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.03.034     Document Type: Article

References (23)

1. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., and Nemeroff C.B. Enhanced neurotensin transmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. The Journal of Neuroscience 21 2 (2001) 601-608
2. Binder E.B., Kinkead B., Owens M.J., and Nemeroff CB. Neurotensin and dopamine interactions. Pharmacological Reviews 53 (2001) 453-486
3. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 41 (2001) 237-260
4. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Research 856 (2000) 48-54
5. Dickinson S.L., Gadie B., and Tulloch I.F. Alpha-1 and alpha-2 adrenoceptor antagonists differentially influence locomotor and stereotyped behavior induced by d-amphetamine and apomorphine in the rat. Psychopharmacologia 96 4 (1988) 521-527
6. Erhardt S., and Engberg G. Increased phasic activity of dopaminergic neurons in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kyenuric acid. Acta Physiologica Scandinavica 175 (2002) 45-53
7. Feifel D., Minor K.L., Dulawa S., and Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Research 760 (1997) 80-84
8. Feifel D., Reza T.L., and Robeck S.L. Pro-dopamine effects of neurotensin on sensorimotor gating effects. Peptides 18 9 (1997) 1457-1460
9. Feifel D., Reza T.L., Wustrow D.J., and Duff Davis M. Novel antipsychotic-like effects on pre-pulse inhibition of startle produced by a neurotensin agonist. Journal of Pharmacology and Experimental Therapeutics 288 (1999) 710-713
10. Fendt M., Schwienbacher I., and Koch M. Amygdaloid N-methyl-d-aspartate and gamma-aminobutyric acid-A receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience 98 (2000) 55-60
11. Geyer M., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of pre-pulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
12. Hedley LR, Secchi RL, Bingham S, Sung E, Richelson E, Button D. The neurotensin agonist NT69L reverses dizocilpine-induced disruption of pre-pulse inhibition in the rat. Soc for Neurosci Abstr #9.5 2002.
13. Mechanic JA, Sutton JE, Pang Z, Button DC, Schreiber R. Pharmacological responsiveness of NTR1 +/+ and NTR1 -/- mice: involvement in the hypothermic, antinociceptive and antipsychotic effects of neurotensin analogs. European Neuropsychopharmacology (2009): corrected proof available online 2009.
14. Mueller K., Kunko P.M., Whiteside D., and Haskett C. Time course of amphetamine-induced stereotypy in an open field. Psychopharmacologia 99 4 (1989) 501-507
15. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., et al. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. Journal of Pharmacology and Experimental Therapeutics 225 2 (1983) 337-345
16. Shilling P.D., Richelson E., and Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug disrupted prepulse inhibition. Behavioral Brain Research 143 (2003) 7-14
17. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophrenia Bulletin 24 2 (1988) 285-301
18. Swerdlow N.R., Martinez Z.A., Hanlon F.M., Platten A., Farid M., Auerbach P., et al. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. The Journal of Neuroscience 20 11 (2000) 4325-4336
19. Swerdlow N.R., Shoemaker J.M., Auerbach P.P., Pitcher L., Goins J., and Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating: II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology 174 (2004) 452-462
20. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Shoemaker J., and Auerbach PP. Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28 (2003) 640-650
21. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., and Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. European Journal of Pharmacology 390 (2000) 107-111
22. Tyler-McMahon B.M., Boules M., and Richelson E. Neurotensin: peptide for the next millennium. Regulatory Peptides 93 (2000) 125-136
23. Widerlöv E., Lindström L., Besev G., Manberg P.J., Nemeroff C.B., Breese G.R., et al. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. American Journal of Psychiatry 139 (1982) 1122-1126